Vaxart Board Approves Reverse Split to Preserve Nasdaq Listing

Vaxart, Inc. has proposed a reverse stock split not exceeding a 1-for-20 ratio, contingent upon stockholder approval, as part of efforts to maintain its Nasdaq listing and avoid delisting. The company’s board also approved a proportional reduction in authorized shares, emphasizing the importance of the Nasdaq listing for shareholder liquidity and attracting institutional investment. CEO Steven Lo highlighted that the reverse split responds to stockholder feedback and is critical for sustaining a stable market presence while advancing their oral recombinant vaccine technology. Despite a nearly 60% stock decline over the past year and ongoing profitability challenges, analysts maintain a strong buy recommendation with price targets averaging around $4.67. Vaxart’s vaccine platform focuses on oral pill vaccines that can be stored without refrigeration, aiming to simplify vaccine administration and distribution. Stockholders are urged to vote in favor of Proposal #2 by the May 20, 2025 deadline to support these strategic measures.